Integragen (ALINT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Integragen (ALINT) has a cash flow conversion efficiency ratio of -1.910x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-645.51K ≈ $-754.67K USD) by net assets (€338.04K ≈ $395.20K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Integragen stock valuation for the company's overall valuation and market capitalisation.
Integragen - Cash Flow Conversion Efficiency Trend (2012–2022)
This chart illustrates how Integragen's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALINT stock price for real-time trading data and today's change.
Integragen Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Integragen ranked by their cash flow conversion efficiency. Review cash generation quality of Integragen to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GO.D.M Investments Ltd
TA:GODM
|
-0.255x |
|
LIFT GLOBAL VENT. LS-01
F:7XO
|
N/A |
|
Desarrolladora Homex S.A.B. de C.V
MX:HOMEX
|
-0.024x |
|
Mitra Komunikasi Nusantara Tbk PT
JK:MKNT
|
-2.611x |
|
Windar Photonics Plc
LSE:WPHO
|
-0.022x |
|
Rivalry Corp
V:RVLY
|
-0.004x |
|
Montfort Capital Corp
V:MONT
|
-2.810x |
|
Subsea 7 SA
LSE:0OGK
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Integragen (2012–2022)
The table below shows the annual cash flow conversion efficiency of Integragen from 2012 to 2022. Also see how large is Integragen's balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €2.20 Million ≈ $2.57 Million |
€403.11K ≈ $471.28K |
0.183x | -2.75% |
| 2021-12-31 | €2.19 Million ≈ $2.56 Million |
€411.78K ≈ $481.41K |
0.188x | -9.62% |
| 2020-12-31 | €2.17 Million ≈ $2.54 Million |
€452.69K ≈ $529.24K |
0.208x | +104.19% |
| 2019-12-31 | €2.51 Million ≈ $2.93 Million |
€256.10K ≈ $299.41K |
0.102x | +109.82% |
| 2018-12-31 | €2.79 Million ≈ $3.27 Million |
€135.90K ≈ $158.88K |
0.049x | +55.07% |
| 2017-12-31 | €3.93 Million ≈ $4.60 Million |
€123.30K ≈ $144.15K |
0.031x | -61.91% |
| 2016-12-31 | €1.28 Million ≈ $1.50 Million |
€105.62K ≈ $123.49K |
0.082x | +102.29% |
| 2013-12-31 | €691.87K ≈ $808.87K |
€-2.49 Million ≈ $-2.91 Million |
-3.592x | -693.04% |
| 2012-12-31 | €3.24 Million ≈ $3.78 Million |
€-1.47 Million ≈ $-1.71 Million |
-0.453x | -- |
About Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and o… Read more